Rab 39A inhibitors are chemical compounds designed to modulate the activity of Rab 39A, a member of the Rab family of small GTPases. Rab 39A is involved in various cellular processes, particularly the regulation of vesicle trafficking and intracellular membrane transport. These inhibitors function by binding to the active site or allosteric sites of the Rab 39A protein, thereby affecting its ability to bind and hydrolyze GTP, an essential aspect of its role in signal transduction. By interfering with Rab 39A's GTPase activity, these inhibitors can effectively regulate downstream processes involving vesicle formation, fusion, and transport, which are critical in cellular homeostasis. The precise mechanisms of action for Rab 39A inhibitors can vary depending on their structure and binding characteristics; some may prevent GTP binding altogether, while others may stabilize the inactive GDP-bound state or disrupt interactions with effector proteins.
Structurally, Rab 39A inhibitors are diverse and can be classified based on their molecular scaffolds, functional groups, and binding interactions. They are often small molecules that exhibit specificity for Rab 39A, although off-target effects can occur, depending on their affinity for other members of the Rab family or related GTPases. Some inhibitors are designed to mimic the natural GTP substrate, while others are more structurally distinct to achieve selectivity. The development of these inhibitors requires a detailed understanding of Rab 39A's three-dimensional structure, particularly its nucleotide-binding domains and conformational changes during activation and inactivation cycles. Additionally, the inhibitors may have different properties affecting their solubility, cell permeability, and stability, which play a role in their effectiveness in modulating Rab 39A activity within cellular systems. By altering Rab 39A function, these inhibitors serve as valuable tools in studying the molecular pathways of vesicular trafficking and the role of Rab 39A in various cellular contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A selective inhibitor of ROCK (Rho-associated protein kinase), Y-27632 may influence Rab 39A activity indirectly by altering actin cytoskeleton dynamics, which is crucial for vesicle transport. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
A potent inhibitor of Cdc42, another member of the Rho family of GTPases. ML141's modulation of Cdc42 might influence Rab 39A activity indirectly through changes in cytoskeletal organization and vesicular trafficking. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
Inhibits cytohesins, which are involved in ARF GTPase activation. By affecting ARF GTPases, SecinH3 might have downstream effects on Rab 39A function in vesicle trafficking. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts ARF1 function and Golgi apparatus structure, potentially influencing Rab 39A activity by altering vesicular transport and protein trafficking pathways. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
A Raf kinase inhibitor that can impact various signaling pathways, potentially influencing Rab 39A activity indirectly through alterations in cell signaling and transport processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK, which is part of the MAPK/ERK pathway. By modulating this pathway, PD98059 may indirectly affect Rab 39A-related vesicular trafficking. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, impacting AKT signaling and potentially influencing Rab 39A activity indirectly through changes in cellular trafficking and growth signals. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor, wortmannin could indirectly affect Rab 39A activity by altering signaling pathways that influence vesicular trafficking and cellular processes. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Inhibits dynamin, a GTPase involved in vesicle scission. Although not directly targeting Rab 39A, dynasore could influence vesicular trafficking processes in which Rab 39A participates. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
Known for modulating endosomal and lysosomal activity, it could indirectly affect Rab 39A's role in vesicular transport by altering the endocytic pathway. | ||||||